Evidence map›Paper›PMID 42266155›Full record

ReviewJournal of medical virology2026

Reverse Genetics of Orthoflaviviruses: Strategies for Constructing Functional or Infectious cDNA.

Young-Min Lee

Abstract readReview
In one paragraph

Review in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Young-Min LeeDepartment of Animal, Dairy, and Veterinary Sciences, College of Agriculture and Natural Resources, Utah State University, Logan, Utah, USA.ORCID https://orcid.org/0000-0002-3974-3405

Funding

National Institute of Allergy and Infectious Diseases R01AI187430Utah Agricultural Experiment Station UTA01655
6 · The paper itself

Abstract

Reverse genetics (RG) systems have transformed RNA virus research by enabling the recovery of recombinant viruses entirely from cloned cDNA. These platforms allow precise, hypothesis-driven manipulation of viral genomes and support systematic phenotypic analyses in vitro and in vivo. Orthoflaviviruses, a genus that includes numerous zoonotic arboviruses associated with neurological and visceral disease, present distinct challenges for RG development. RNA-launched systems, which rely on in vitro transcription of infectious RNA from a full-length functional cDNA clone, have long been the standard approach. However, the technical demands of RNA synthesis and handling have increased interest in DNA-launched systems that initiate virus recovery directly from a full-length infectious cDNA clone. Despite these advances, constructing genetically stable full-length orthoflavivirus cDNA clones remains difficult because certain genomic regions are unstable or toxic during bacterial propagation. To address these obstacles, conventional bacteria-based cloning has been supplemented with bacteria-free strategies such as long-distance reverse transcription-PCR, circular polymerase extension reaction, Gibson isothermal assembly, and infectious subgenomic amplicons. This commentary summarizes the key features, strengths, and limitations of current RNA- and DNA-launched RG systems for orthoflaviviruses, with emphasis on the technical challenges unique to this group. Together, these perspectives provide a framework for selecting and implementing RG approaches tailored to orthoflaviviruses.

Indexed as

DNA, ComplementaryFlaviviridaeReverse GeneticsAnimalsCloning, MolecularGenome, ViralHumansRNA, ViralDNA, ComplementaryRNA, Viralflavivirusfunctional cDNAinfectious cDNAorthoflavivirusreverse genetics

Identifiers

PMID42266155
PMCPMC13250680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.